30 closest matches · ranked by relevance
Pancreatic Cancer · Pancreatic Adenocarcinoma · Pancreas Ductal Adenocarcinoma
Primary: R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins — 9; 9 participants with resectable PDAC
Adenocarcinoma of the Pancreas · Stage IA Pancreatic Cancer · Stage IB Pancreatic Cancer
Primary: Median Overall Survival of Patients With Adenocarcinoma of the Pancreas — 31.6 months
Resectable Pancreatic Cancers
Primary: Feasibility as Measured by Number of Participants Who Complete the Neoadjuvant Gemcitabine/Nab-paclitaxel and HIGRT Regimen — 39 Participants
Pancreatic Cancer
Primary: Number of Participants With Resectability Rate — 15 Participants
Pancreatic Cancer
Primary: Biochemical Response Rate — 383; 550; 43; 53 U/mL
Pancreatic Cancer
Primary: Local Progression-free Survival (LPFS) — 22.30801 months
Pancreatic Cancer
Primary: The Percentage of Patients That Underwent an R0 Resection — 52 percentage of patients
Pancreatic Cancer
Primary: Recurrence Free Survival — 15.6 months
Pancreatic Adenocarcinoma
Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants
Pancreatic Cancer
Primary: Rate of Margin Negative Surgical Resection (R0 Resection Rate) — 88 percentage of participants
Pancreatic Adenocarcinoma
Primary: Percentage Able to Complete Full Course of Preoperative Chemotherapy — 22 Participants
Pancreatic Adenocarcinoma
Primary: Number of Participants With Relapse-free Survival — 3; 2 Participants
Pancreatic Cancer
Primary: Number of Participants With Acute (Within 3 Months of Treatment) Grade 3 or Greater Gastrointestinal Toxicity — 0 Participants
Resectable Pancreatic Cancer · Unresectable Pancreatic Cancer · Pancreatic Adenocarcinoma
Primary: CA 19-9 Normalization — 40; 13.6; 30; 50 Percentage of participants — p=0.235
Pancreatic Cancer
Primary: Feasibility of Adjuvant FOLFOX-A — 18 Participants
Pancreas Neoplasm Malignant Resectable
Primary: Frequency of R0 Resection — 11; 2 Participants
Histologically or Cytologically Confirmed Pancreatic Ca · Unresectable or Borderline Resectable Pancreatic Ca
Primary: Number of Participants With Dose Limiting Toxicity (DLT ) — 0; 1; 0; 0 Participants
Pancreatic Carcinoma
Primary: Number of Serious Pre-operative, Operative and Post-operative Adverse Events to 120 Days Post Randomization or to 30 Days Post Surgery, Whichever Comes Last — 40; 36…
Adenocarcinoma of the Pancreas
Primary: Local Progression-free Survival (LPFS) at 1-year — 85 percentage of participants
Pancreatic Cancer
Primary: Overall Survival at 18 Months — 63 percentage of participants
Pancreatic Cancer
Primary: Two-year Disease Free Survival. — 26.1 percentage of patients
Pancreatic Cancer
Primary: Overall Survival — 24.8 Months
Pancreatic Cancer
Primary: Survival — 37; 31 participants
Resectable Pancreatic Ductal Adenocarcinoma (PDAC) · Pancreatic Ductal Adenocarcinoma
Primary: Pathologic Complete Response (pCR) Rate — 0; 0 Percentage of participants
Pancreatic Cancer
Primary: Progression-free Survival — 9.2; 8.9 months
Resectable Pancreatic Ductal Adenocarcinoma
Primary: Percentage of Patients With Pathologic Complete Response — 0 percentage of participants
Pancreatic Neoplasms
Primary: Acute Toxicity Rates of Grade 3 or Greater Gastrointestinal and Hematologic Toxicities (as Raw Percentage) — 13.89; 0.00; 2.78; 0.00 percentage of participants
Pancreatic Cancer · Periampullary Adenocarcinoma
Primary: Late Gastrointestinal Toxicities — 13 Participants
Pancreatic Cancer
Primary: Dose Limiting Toxicities — 0; 0; 1; 3 Participants
Pancreatic Cancer
Primary: Percent of Patients Experiencing an Unacceptable Toxicity — 6.67; 6.67 Percentage of Participants